This database contains 1063 studies, archived under the term: "female"
Click here to filter this large number of results.
Detecting MCI and dementia in primary care: effectiveness of the MMS, the FAQ and the IQCODE corrected
Cruz-Orduña, Isabel,
Bellón, José M.,
Torrero, Pedro,
Aparicio, Esperanza,
Sanz, Ana,
Mula, Nieves,
Marzana, Garbiñe,
Begué, Concepción,
Cabezón, Dionisio,
Olazarán, Javier
Objectives: To study the yield of three instruments for detection of patients with cognitive impairment in primary care. To investigate whether combining tests is better for detecting impairment than applying them separately.; Methods: Seven primary care physicians (PCP) systematically recruited individuals aged over 49 years with a complaint or suspicion of cognitive impairment. The tests […]
Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer’s disease: a pilot study
Carlsson, Cynthia M.,
Xu, Guofan,
Wen, Zhifei,
Barnet, Jodi H.,
Blazel, Hanna M.,
Chappell, Richard J.,
Stein, James H.,
Asthana, Sanjay,
Sager, Mark A.,
Alsop, David C.,
Rowley, Howard A.,
Fain, Sean B.,
Johnson, Sterling C.
Background/aims: Hypercholesterolemia in midlife increases risk for Alzheimer’s disease (AD) and contributes to cerebrovascular dysregulation – an early finding in preclinical AD pathology. Statins improve vascular reactivity, but it is unknown if they increase regional cerebral blood flow (CBF) in individuals at risk for AD.; Methods: In a randomized, controlled, double-blind pilot study, 16 asymptomatic […]
Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease
Burstein, Aaron H,
Zhao, Qinying,
Ross, Joel,
Styren, Scot,
Landen, Jaren W.,
Ma, Wendy W.,
McCush, Fred,
Alvey, Christine,
Kupiec, James W.,
Bednar, Martin M.
Objective: Ponezumab (PF-04360365) is a humanized anti-amyloid beta (Aβ) monoclonal antibody designed for treatment of Alzheimer disease (AD). A single 2-hour intravenous infusion of 0.1 to 10 mg/kg was previously shown to be safe and well tolerated in subjects with mild to moderate AD, with measurable effects on plasma and cerebrospinal fluid Aβ. This phase […]
Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids
Blackburn, Daniel J.,
Krishnan, Kailash,
Fox, Lydia,
Ballard, Clive,
Burns, Alistair,
Ford, Gary A.,
Mant, Jonathan,
Passmore, Peter,
Pocock, Stuart,
Reckless, John,
Sprigg, Nikola,
Stewart, Rob,
Wardlaw, Joanna,
Bath, Philip M. W.
Background: Stroke is a common cause of cognitive impairment and dementia. However, effective strategies for reducing the risk of post-stroke dementia remain undefined. Potential strategies include intensive lowering of blood pressure and/or lipids.; Design: multi-centre prospective randomised open-label blinded-endpoint controlled partial-factorial phase IV trial in secondary and primary care.; Participants: 100 participants from 30 UK […]
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment
Bakker, Arnold,
Krauss, Gregory L.,
Albert, Marilyn S.,
Speck, Caroline L.,
Jones, Lauren R.,
Stark, Craig E.,
Yassa, Michael A.,
Bassett, Susan S.,
Shelton, Amy L.,
Gallagher, Michela
Elevated hippocampal activation is observed in conditions that confer risk for Alzheimer’s disease, including amnestic mild cognitive impairment (aMCI). Studies in relevant animal models have indicated that overactivity in selective hippocampal circuits contributes to cognitive impairment. Here, we tested the effect of reducing hippocampal activation in aMCI. Under placebo treatment, hippocampal activation in the dentate […]
High-intensity physical activity modulates diet effects on cerebrospinal amyloid-β levels in normal aging and mild cognitive impairment
Baker, Laura D.,
Bayer-Carter, Jennifer L.,
Skinner, Jeannine,
Montine, Thomas J.,
Cholerton, Brenna A.,
Callaghan, Maureen,
Leverenz, James B.,
Walter, Brooke K.,
Tsai, Elaine,
Postupna, Nadia,
Lampe, Johanna,
Craft, Suzanne
We previously showed that amyloid-β 1-42 (Aβ(42)) levels in cerebrospinal fluid (CSF) were markedly altered in response to a 4-week dietary intervention in normal aging and mild cognitive impairment (MCI). Here, we re-examined the data to assess whether diet-induced effects on CSF Aβ(42) were modulated by high intensity physical activity (hi-PA). Normal older adults (n […]
Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer’s patients–an open-label trial
Kennelly, Sean,
Abdullah, Laila,
Kenny, Rose Anne,
Mathura, Venkat,
Luis, Cheryl A.,
Mouzon, Benoit,
Crawford, Fiona,
Mullan, Michael,
Lawlor, Brian
Background: Evidence suggests that dihydropyridine calcium channel blockers may be useful in preventing and treating Alzheimer’s disease (AD).; Objective: In an open-label trial of safety and tolerability of nilvadipine in patients with AD, we examined cognition and executive function over a short time period to determine an influence of nilvadipine on these outcomes.; Method: We […]